On the ropes, Opexa shares blast­ed by PhI­Ib mul­ti­ple scle­ro­sis tri­al flop

Opexa Ther­a­peu­tics $OPXA to­day be­comes the lat­est in a long line­up of pub­lic biotech com­pa­nies to feel the wrath of dis­ap­point­ed in­vestors in the wake of a clin­i­cal tri­al fail­ure. The biotech’s shares cratered, plung­ing 69% in pre-mar­ket trad­ing af­ter its lead ther­a­py flunked a Phase IIb for mul­ti­ple scle­ro­sis.

The news wiped out the li­on’s share of The Wood­lands, TX-based biotech’s mi­nus­cule $24 mil­lion in mar­ket cap.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.